Not recruiting
Neoplasm+1
Not recruitingStudy on Niraparib and Dostarlimab for Patients with DNA Repair-Deficient or Platinum-Sensitive Solid Tumors
Registered drugNo placebo
Study on Niraparib and Dostarlimab for Patients with DNA Repair-Deficient or Platinum-Sensitive Solid Tumors
Registered drugNo placebo
- Disease:NeoplasmDNA mismatch repair deficiency test
- Substances:DostarlimabNiraparib
Countries:
France
France- Participants:18–64 years · 65+ years · Healthy volunteers
- Substances:Dostarlimab
- Sponsor:Institut Gustave Roussy
